Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01844986 · ClinicalTrials.gov registry record · Phase 3

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

A Phase 3 study of BRCA Mutation and Advanced Ovarian Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
450
Enrollment target
20
Study locations

NCT01844986 is a Phase 3 study of BRCA Mutation and Advanced Ovarian Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 450 participants, above the 120-participant average among 4 other BRCA Mutation trials with a reported enrollment target (275% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01844986, a Phase 3 study of BRCA Mutation and Advanced Ovarian Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

Conditions Studied

BRCA Mutation Advanced Ovarian Cancer Newly Diagnosed FIGO Stage III-IV Complete Response Partial Response First Line Platinum Chemotherapy

Interventions

  • DRUG Olaparib 300mg tablets

Study Locations (20)

California

  • Cedars-Sinai Medical Center - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • Kaiser Permanente - Oakland
  • Kaiser Permanente - Roseville
  • Stanford Women's Cancer Center - Stanford
  • Babak Edraki - Walnut Creek

Florida

  • Florida Hospital Cancer Institute - Orlando
  • Gynecologic Cancer Center - Orlando
  • H Lee Moffitt Cancer Center and Research Institute - Tampa

Georgia

  • Northside Hospital - Atlanta
  • Northeast Georgia Medical Center - Gainesville
  • Nancy N. & J.C. Lewis Cancer and Research Pavillion - Savannah

Connecticut

  • Univ of Connecticut Health Center - Farmington
  • Smilow Cancer Hospital at Yale New Haven - New Haven

Hawaii

  • The Queen's Medical Center - Honolulu
  • University of Hawaii - Honolulu

Alabama

  • Clearview Cancer Institute - Huntsville

Alaska

  • Providence Cancer Center - Anchorage

Arizona

  • St. Joseph's Hospital & Medical Center - Phoenix

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2013-08-26
Est. Completion 2028-08-29
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01844986

The ClinicalTrials.gov registry entry for NCT01844986 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 120-participant average among 4 other BRCA Mutation trials with a reported enrollment target (275% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with BRCA Mutation appearing as the primary indexed condition, and to 1 intervention - of which Olaparib 300mg tablets is the first listed.

NCT01844986 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT01844986 about?

NCT01844986 is a clinical study titled "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.". Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.

What is the current status of trial NCT01844986?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2013-08-26. Estimated completion is 2028-08-29.

What conditions does trial NCT01844986 study?

This clinical trial studies the following conditions: BRCA Mutation, Advanced Ovarian Cancer, Newly Diagnosed, FIGO Stage III-IV, Complete Response.

What interventions are being tested in trial NCT01844986?

The interventions under investigation include: Olaparib 300mg tablets (DRUG).

Who is sponsoring clinical trial NCT01844986?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01844986 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for BRCA Mutation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

BRCA Mutation

All registered trials for this condition

Advanced Ovarian Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.